NHS access to GLP-1 weight management medications: the patient pathway

Hero capsule

NHS access to a GLP-1 medication for weight loss is a process, not a transaction. The current pathway in England, in May 2026, runs through three gates. The first gate is your GP, who decides whether to refer you onward. The second gate is a Tier-3 specialist weight management service, which assesses you, enrols you in a structured programme, and only then considers prescribing. The third gate is your local Integrated Care Board, the body that decides what its area actually commissions and at what scale. NICE Technology Appraisal TA1026 sets the eligibility criteria for tirzepatide (Mounjaro) for weight management on the NHS, but criteria on paper and access on the ground are not the same thing. This guide walks through the patient pathway, the eligibility framework, what happens at each appointment, the regional variation in wait times, and the private alternative if NHS access is not available where you live, or not available yet, or not available for you.

The patient pathway, end to end

Most people arrive at GLP-1 conversations after months of frustration, often a year or more, sometimes after a decade of weight cycling. The route into NHS prescribing is more structured than people expect, and the structure is largely a good thing. It is designed to catch the people who will benefit most, screen out the people for whom the medication carries unacceptable risk, and embed pharmacological treatment inside a behavioural and dietary programme rather than as a stand-alone fix.

The pathway typically looks like this.

You book an appointment with your GP. You raise weight as the topic. The GP performs basic anthropometric measurements, reviews your medical history, and either refers you to a Tier-3 service or declines to refer. There is no obligation on the GP to refer, and there is no automatic right to a referral. If your GP declines, you can request a second opinion within the practice, but you cannot compel a referral. We will return to this scenario in the FAQ.

If you are referred, the referral lands in your local weight management service waiting list. Wait times here are the single biggest variable in the entire pathway, and they vary not by months but by years in some Integrated Care Board areas. We cover this in detail below.

When you reach the front of the queue, you attend an initial assessment with the weight management service. This is usually a multidisciplinary team appointment with a dietitian or specialist nurse, and sometimes a clinical psychologist. The team reviews your eligibility against NICE TA1026, assesses comorbidities, reviews medications, and decides whether you are a candidate for the medical pathway, the behavioural pathway, or both in parallel.

If pharmacological treatment is offered, it is offered as part of a structured programme that includes dietary input, physical activity guidance, behavioural support, and regular follow-up. Prescribing decisions are made by the service, not transferred to your GP, certainly not in the first year. Follow-up cadence varies by service but is usually monthly for the initial titration period and quarterly thereafter.

Tier-4 sits above Tier-3 and refers to specialist multidisciplinary services that include bariatric surgery as part of their remit. Tier-4 referrals are typically for the highest BMI thresholds and for people whose Tier-3 programme has not delivered the clinical outcome required.

That is the pathway in outline. It is genuinely a pathway. There is no shortcut through it on the NHS in 2026.

Eligibility per NICE TA1026

NICE Technology Appraisal TA1026, published in 2024, sets the criteria for tirzepatide (Mounjaro) for weight management on the NHS. Before reading the criteria, please read this sentence carefully. The criteria are guidance for clinicians. They are not a checklist you can apply to yourself. Your GP and your weight management service apply them. We are summarising them for editorial context only.

The headline thresholds in TA1026 are a body mass index of at least 35 kg/m², combined with at least one weight-related comorbidity. The recognised comorbidities include type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, and cardiovascular disease. The threshold drops to a BMI of at least 30 kg/m² for people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background, in recognition that cardiometabolic risk presents at lower BMI levels in these groups.

There are also contraindications and cautions that the prescribing clinician will consider. A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, is a contraindication. Pregnancy and breastfeeding are contraindications. A history of pancreatitis is a caution that requires careful weighing. Severe gastrointestinal disease, including gastroparesis, is a caution. People on other glucose-lowering therapies, particularly insulin or sulfonylureas, require careful titration to reduce hypoglycaemia risk.

NICE TA1026 also sets stopping rules. The guidance specifies that treatment is reviewed at intervals, and if a certain percentage of initial body weight has not been lost by a defined time point, the medication is stopped. The exact percentages and time points are clinical thresholds we are not going to reproduce here, because the meaningful application of those thresholds belongs to your prescriber, who knows your starting point, your trajectory, and your wider clinical picture.

The crucial editorial point is this. Eligibility on paper is necessary but not sufficient. Your local Integrated Care Board decides how the NICE guidance is commissioned in your area. Some ICBs commission the full population eligible under TA1026. Others commission a phased rollout, prioritising the highest BMI bracket or particular comorbidity profiles in the first cohort. Others have funded only a pilot, with a hard cap on patient numbers. The ICB rollout tracker is our live attempt to surface what each area is actually doing, and we update it as ICBs publish their plans.

What happens at the weight management service appointment

The first weight management service appointment usually lasts between thirty and sixty minutes. Bring your medication list, your most recent blood test results if you have them, and a brief written history of your weight trajectory, previous attempts at weight loss, and any conditions you are managing.

The appointment is an assessment, not a prescribing visit. The team is building a clinical picture. They will measure weight, height, blood pressure, and waist circumference. They will ask about diet, physical activity, sleep, mood, alcohol intake, smoking, family history, and current medications. They will ask about previous engagement with weight management, including diets, behavioural programmes, and any prior pharmacotherapy. They may order blood tests if recent results are not available, including HbA1c, lipid panel, liver function, thyroid function, and a renal panel.

Following the assessment, you will usually be enrolled in a structured programme. The programme has a behavioural component, a dietary component, and a physical activity component. Some services run group sessions, some run one-to-one appointments, and many run a hybrid. The programme is not optional in the sense that pharmacotherapy is generally offered alongside it, not instead of it. The evidence base for GLP-1 medication in weight management is built on combined intervention, and NHS commissioning reflects this.

If you are a candidate for pharmacotherapy, the prescribing decision is made by the service. The prescription is usually written within the service for the first phase of treatment, with monthly follow-up during titration. Titration is the period in which the dose is increased gradually to the therapeutic level. The follow-up schedule allows the team to monitor tolerability, manage side effects, and adjust the pace of titration if needed.

After the first phase, some services hand prescribing back to your GP under a shared care agreement, with the service retaining specialist oversight. Other services keep prescribing in-house for the duration of treatment. This varies by ICB area and by the local shared care framework.

The Tier-3 weight management service and regional variation

Tier-3 is the NHS specialist weight management tier. It sits between primary care, which is Tier-1 and Tier-2 in the obesity care framework, and bariatric surgical services, which is Tier-4. Tier-3 is multidisciplinary. A full Tier-3 service has medical, dietetic, psychological, and physical activity input, with clinical leadership usually from a consultant in diabetes, endocrinology, or specialist obesity medicine.

The reason GLP-1 prescribing typically requires Tier-3 enrolment is twofold. The first reason is clinical. GLP-1 medications are most effective when combined with behavioural and dietary support, and Tier-3 is the NHS infrastructure designed to deliver that combination. The second reason is governance. Tier-3 services hold the clinical risk for specialist prescribing, including the assessment of contraindications, the titration schedule, side-effect management, and stopping criteria. Most primary care prescribers do not currently hold individual scope for first-line specialist GLP-1 initiation for weight management. The service holds it.

Regional variation is significant. Some ICB areas have well-staffed Tier-3 services with capacity to accept new referrals. Others have Tier-3 services that exist on paper but are running at multi-year wait lists. A few areas have moved to commission GLP-1 prescribing in primary care, under enhanced service arrangements with specific training and audit requirements, but this is the exception rather than the rule in May 2026.

The London ICBs, the major metropolitan ICBs in the North West and the West Midlands, and some of the better-resourced South East ICBs have more developed services. Several rural ICBs, ICBs in coastal areas, and ICBs that inherited weak weight management commissioning from predecessor Clinical Commissioning Groups have substantially less capacity.

Our ICB rollout tracker maps this in detail. It is the companion piece to this guide and is updated as ICBs publish their commissioning intentions.

Wait times: what is actually realistic

There is no point pretending the wait times are short. Published NHS England data on Tier-3 weight management waits is patchy compared with the data published on, for example, joint replacement or cataract pathways, partly because Tier-3 is not a Referral to Treatment pathway in the same statutory sense. Most of the published data comes from individual ICB papers, from Freedom of Information responses, and from secondary analysis by specialist commentators.

Honest editorial commentary based on that picture in 2026 is this. In well-resourced areas, the wait from GP referral to first Tier-3 appointment is typically six to twelve months. In mid-tier areas, eighteen to twenty-four months is common. In the most stretched areas, waits of three years or more have been reported, and some services have been temporarily closed to new referrals. The wait to first appointment is followed by the wait from assessment to programme start, which is usually shorter but adds further weeks or months.

The arrival of GLP-1 medications has substantially increased demand. The publicity around tirzepatide and semaglutide has brought a population of patients into the pathway who, before 2023, would not have presented to weight management services at all. This has compounded pre-existing capacity constraints rather than triggered a proportional commissioning response. The funding has expanded, but not at the pace of demand.

We say this not to discourage. We say it because the alternative, which is the rhetorical claim that NHS GLP-1 access is widely available and quick, would be misleading. It is not. The medication exists, the eligibility framework exists, the commissioning framework exists, and the capacity to deliver it at population scale does not yet exist.

The realistic posture for a patient considering the NHS pathway is to start the referral process now, accept that the wait may be long, use the wait period productively for the lifestyle changes that will be required at the assessment anyway, and consider whether a private route alongside or instead of the NHS pathway is appropriate.

The private alternative

Not everyone can access the NHS pathway. There are several reasons for this. You may not meet the NICE eligibility threshold but still have a clinical case for treatment, in your view and in the view of a private prescriber. Your local ICB may not yet commission GLP-1 prescribing under TA1026, or may have commissioned only a small initial cohort. Your GP may have declined to refer. Your GP practice may be a private contractor, which does not change your NHS eligibility but can complicate the pathway. The Tier-3 wait in your area may be a year, or two, or longer, and the decision to wait may not be the right decision for you.

The private pathway in the UK in 2026 is, on the whole, well organised. Reputable UK clinics, including the providers we cover in our clinic directory, run their own clinical assessment, have GMC-registered prescribers, dispense through MHRA-registered UK pharmacies, and offer structured programmes that mirror the Tier-3 evidence base in style if not in funding. The cost is real. Monthly costs for a private GLP-1 programme in the UK currently sit in the range of one hundred and fifty to three hundred pounds, depending on the medication, the dose phase, and what is bundled into the programme.

Some people choose private even when NHS-eligible. The reasons are usually pragmatic. Time to first appointment is days or weeks rather than months. The programme structure is consistent. Clinical contact is continuous. And there is no question of stopping rules being triggered by a missed appointment in a stretched service.

Some people cannot reasonably do anything else. If you have been on a waiting list for two years, if you have tried every recognised behavioural programme, and if your weight-related health is deteriorating, the private route is not a luxury. It is a clinical decision taken with a private prescriber.

We do not recommend a specific clinic or pharmacy for a specific person. We publish editorial profiles of the UK clinics and UK pharmacies that operate in this space. Browse our /clinics/ directory and /pharmacies/ directory for the current list and our editorial notes on each.

Switching from private to NHS

This question comes up frequently. You are on a private GLP-1 programme. Your local ICB commissions Tier-3 prescribing under TA1026. You wonder whether you can switch.

In principle, yes. The mechanism is the same as for any other patient. You ask your GP for a Tier-3 referral. You attend the assessment. The Tier-3 service decides whether to take you onto its medical pathway. The fact that you are already on a GLP-1 medication is a clinical detail the service will consider, not an automatic disqualification and not an automatic acceptance.

In practice, the transition is more complicated than it sounds. The Tier-3 service may want a wash-out period, a switch to a different medication, or a different titration approach. The NHS prescribing decision is independent of the private prescribing decision, and there is no formal handover protocol between private and NHS providers in most ICB areas. Your private clinician will usually write a summary letter for the NHS service, and the NHS service will treat that letter as one piece of evidence in its own assessment.

Wait times still apply. The route from “I am on private Mounjaro” to “I am on NHS Mounjaro” is not faster than the route from no treatment to NHS treatment, in most cases. The Tier-3 wait is the rate-limiting step, and being on a private programme does not move you up the queue.

A practical consideration for people who do make the switch is the gap between private supply ending and NHS supply starting. Most private programmes will continue to supply until the NHS prescription is in your hand, but this should be confirmed in writing with both providers before stopping or switching anything.

What we are not saying

This is the section the regulatory framework requires us to be explicit about, and it is also the section that matters most.

We do not determine eligibility for any specific person. Your GP determines whether you are referred. The Tier-3 weight management service determines whether you are accepted onto the medical pathway. The prescribing clinician determines whether a medication is appropriate for you. We are an editorial publication. We summarise the framework. We do not apply it to you.

We do not give clinical advice. Nothing on PeptideClear is a substitute for advice from your GP, your weight management service, or your prescriber. If you have a clinical question, ask a clinician. If you are unwell, contact NHS 111 or your GP, or in an emergency call 999.

We do not recommend specific medications, specific doses, or specific prescribers for specific people. We profile UK clinics and UK pharmacies for editorial transparency. The decision about who to use, and whether to use any of them, is yours and your clinician’s.

We do not publish dosing protocols, titration schedules, or off-label use guidance. Where doses or schedules are referenced in this guide, they are referenced at the level of “your prescriber will manage the titration”, not at the level of specific numbers.

FAQ

Am I eligible for NHS GLP-1 prescribing for weight loss?

We cannot tell you. The NICE TA1026 framework above is the criteria your GP and Tier-3 service will apply. The headline thresholds are a BMI of at least 35 kg/m² with a weight-related comorbidity, or 30 kg/m² for certain family background groups, with contraindications and cautions assessed individually. Your GP decides whether you meet the bar for referral. The Tier-3 service decides whether you meet the bar for prescribing.

How long is the wait?

It varies by area. In well-resourced ICBs, six to twelve months from GP referral to first Tier-3 appointment is typical. In mid-tier areas, eighteen to twenty-four months. In the most stretched areas, three years or more has been reported. The ICB rollout tracker is the place to check the picture in your specific area.

What if my GP says no?

You can request a second opinion within the practice. You can ask the GP to record the reason for the refusal. You can request that the GP write to your local Tier-3 service for advice on whether a referral would be accepted. You cannot compel a referral. If you believe the refusal is unreasonable, the formal route is a complaint via the practice manager, and if that does not resolve, via NHS England. The private pathway is also available.

Can I have NHS Mounjaro while my private course continues?

No. You will not be prescribed the same medication in parallel by both NHS and private providers. A switch is possible, with the wait times noted above, and with planning between providers to avoid a supply gap. Talk to both your private clinician and your NHS service about the timing.

Does my GP have to refer me to Tier-3 if I meet the criteria?

No. Referral is a clinical decision, not an entitlement. A GP can refuse to refer if they do not believe the referral is clinically appropriate, or if the local Tier-3 service is not accepting new referrals, or for other reasons. In practice, most GPs will refer if the patient meets the threshold and asks for the referral.

Is the GLP-1 prescription transferred to my GP after the Tier-3 service starts it?

Sometimes, eventually. The first phase of treatment is almost always managed by the Tier-3 service. After titration, some services hand prescribing to the GP under a shared care agreement, with specialist oversight retained. Others keep prescribing within the service. This is set locally by each ICB and each service.

Sources

NICE Technology Appraisal TA1026, Tirzepatide for managing overweight and obesity, National Institute for Health and Care Excellence, 2024.

NHS England, Obesity care pathway, the four-tier model, NHS England commissioning guidance.

NHS England, Commissioning for tirzepatide for weight management, 2024 to 2026 phased rollout documents.

Royal College of Physicians, Action on Obesity, Tier-3 weight management service standards.

British Obesity and Metabolic Surgery Society, Tier-3 and Tier-4 service framework.

Individual Integrated Care Board commissioning policies for tirzepatide and semaglutide, as referenced and updated in our ICB rollout tracker.

This guide is editorial commentary and not clinical advice. Your GP and your weight management service determine your eligibility, your treatment plan, and your prescribing. If you have a clinical question, speak to a clinician.